Clinical Trials on Urinblære, overaktiv

Total 765 results

Astellas Pharma Inc

Completed

Efficacy & Safety Study of VESIcare® (Solifenacin Succinate) in Patients Wishing to Switch From Detrol LA® for Treatment of Overactive Bladder (VERSUS)

Urinary Bladder, Overactive

United States
Astellas Pharma Inc

Completed

Solifenacin Succinate Versus Tolterodine 4mg Once Daily (STAR)

Urinary Bladder, Overactive

France, United Kingdom, Spain, Belarus, Belgium, Ukraine, Denmark, Greece, Russian Federation, Czech Republic, Netherlands, Germany, Hungary, Italy, Slovakia, Sweden, Norway
Pfizer

Completed

Local, Open-Label, Extension Trial Of The Efficacy And Safety Of Fesoterodine In Elderly Patients With Overactive Bladder

Urinary Bladder, Overactive

Portugal
Pfizer

Terminated

Non-Interventional Study To Investigate Whether Information Provided To Patients Influences Their Satisfaction With Toviaz Therapy

Urinary Bladder, Overactive
Pfizer

Completed

Special Investigation For Long Term Use Of Tolterodine (Regulatory Post Marketing Commitment Plan).

Urinary Bladder, Overactive
Rambam Health Care Campus

Unknown

Solifenacin Succinate Versus Fesoterodine A Comparison Trial for Urgency Symptoms

Urinary Bladder, Overactive

Israel
Bayer

Completed

A Trial to Learn How a New Liquid Form of BAY1817080 is Tolerated and Taken up by the Body of Healthy Male Participants (Part A). By Labeling BAY1817080 With a Radioactive Substance (Carbon 14) Researchers Want to Learn How the Study Drug is Processed and Excreted by the Body After Dosing (Part B)

Overactive Bladder | Diabetic Neuropathic Pain | Endometriosis Related Pain | Refractory or Unexplained Chronic Cough

Netherlands
Daniel Burdick, MD
Astellas Pharma US, Inc.

Completed

A Pilot Study of Mirabegron and Behavioral Modification Including Pelvic Floor Exercise for Overactive Bladder in Parkinson's Disease (MAESTRO) (Maestro)

Parkinsons Disease

United States
Valencia Technologies Corporation

Recruiting

A Real World Study of eCoin for Urgency Urinary Incontinence: Post Approval Evaluation (RECIPE) (RECIPE)

Overactive Bladder | Urge Incontinence | Urinary Urge Incontinence | Incontinence, Urinary

United States
Valencia Technologies Corporation

Active, not recruiting

Pivotal Study of eCoin for Overactive Bladder With Urgency Urinary Incontinence

Overactive Bladder | Urge Incontinence | Urinary Urge Incontinence | Incontinence, Urinary

United States
GlaxoSmithKline

Completed

Efficacy and Safety of GSK1358820 in Subjects With Overactive Bladder

Urinary Bladder, Overactive

Japan
Astellas Pharma Europe B.V.

Completed

A Clinical Study to Investigate How Solifenacin Fluid is Taken up, How Long it Stays in the Body and How Effective and Safe it is in Treating Children Aged From 6 Months to Less Than 5 Years With Symptoms of Neurogenic Detrusor Overactivity (NDO)

Pediatric | Neurogenic Detrusor Overactivity

United States, Belgium, Korea, Republic of, Philippines, Poland, United Kingdom
Astellas Pharma Europe Ltd.

Completed

A Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Patients With Overactive Bladder Who Were Previously Treated With Another Medicine But Were Not Satisfied With That Treatment. (BEYOND)

Urologic Diseases | Urinary Bladder, Overactive | Urinary Bladder Diseases

Greece, Ireland, Armenia, Austria, Belarus, Belgium, Bulgaria, Canada, Czechia, Denmark, Finland, France, Georgia, Germany, Hungary, Italy, Kazakhstan, Latvia, Lebanon, Lithuania, Netherlands, Norway, Poland, Portugal, Russian Federation, Slovaki... and more
University of North Carolina, Chapel Hill
American Urogynecologic Society

Completed

The Effect of Anticholinergics on Cognitive Function in the Elderly (ACE)

Urinary Bladder, Overactive | Cognitive Function | Mental Competency

United States
Astellas Pharma Inc

Completed

A Study to Evaluate Safety and Efficacy of YM178 in Patients With Overactive Bladder

Urinary Bladder, Overactive

Japan
Maastricht University Medical Center

Unknown

Brain Areas Involved in Bladder Filling and Contraction

Urinary Bladder, Overactive

Netherlands
Astellas Pharma Europe B.V.

Completed

A Study to Assess the Long Term Effect, Safety and Metabolism of a Solifenacin Liquid Suspension in Participants 5 to 18 Years of Age With Neurogenic Detrusor Overactivity

Neurogenic Detrusor Overactivity

United States, Belgium, Brazil, Denmark, Hungary, Korea, Republic of, Mexico, Philippines, Poland, Turkey
Collegium Medicum w Bydgoszczy

Unknown

Effects of Urinary Bladder Hypertrophy on Urge Urine Incontinence After Radical Prostatectomy

Overactive Bladder | Prostate Cancer | Urinary Incontinence, Urge | Incontinence | Prostatectomy
Astellas Pharma Inc

Completed

A Study of YM178 in Subjects With Symptoms of Overactive Bladder

Urinary Bladder, Overactive

China, Taiwan, India, Korea, Republic of
Allergan

Completed

Safety and Efficacy Study of AGN-214868 in Patients With Idiopathic Overactive Bladder and Urinary Incontinence

Urinary Bladder, Overactive

France, United States, Netherlands
Pfizer

Completed

A Study to Compare the Effectiveness and Safety of Fesoterodine and Placebo in an Elderly Population of Patients Who go to the Toilet Very Frequently Due to Overactive Bladder. (SOFIA)

Urinary Bladder, Overactive

Portugal, Spain, Turkey, Finland, Germany, Norway, Sweden, Slovakia, Italy, Austria, United Kingdom, Belgium, Denmark, Israel, Switzerland
Boston Urogynecology Associates

Recruiting

High Intensity Focused Electromagnetic Field Device for Urinary Incontinence

Overactive Bladder | Stress Urinary Incontinence | Urge Incontinence | Urge and Stress

United States
Omri Schwarztuch Gildor

Enrolling by invitation

Sacral Neuromodulation in Neurogenic Patients

Overactive Bladder | Neurogenic Bowel | Fecal Incontinence | Urge Incontinence | Neurogenic Bladder | Retention, Urinary

Israel
Rose Khavari, M.D.
The Methodist Hospital Research Institute

Completed

Central Nervous System Changes Following BotulinumtoxinA Injection in the Bladder

Multiple Sclerosis | Lower Urinary Tract Symptoms | Urge Incontinence | Neurogenic Bladder | Detrusor, Overactive

United States
Northwell Health
Medtronics, Inc.

Completed

UNGF Assessment in Patients With Detrusor Overactivity Undergoing Sacral Neuromodulation

Detrusor Overactivity

United States
University of Michigan
Society for Urodynamics & Female Urology (SUFU) Research Foundation

Completed

PTNS on Urinary and Global Quality of Life in MS Patients (PTNSinMS)

Multiple Sclerosis | Overactive Bladder | Lower Urinary Tract Symptoms | Urinary Incontinence | Neurogenic Bladder | Urinary Urge Incontinence

United States
Pfizer

Completed

BIOEQUIVALENCE STUDY IN HEALTHY PARTICIPANTS COMPARING 4 MG AND 8 MG FESOTERODINE EXTENDED-RELEASE TABLETS (TOVIAZ™), MANUFACTURED AT ZWICKAU VERSUS FREIBURG

Neurogenic Detrusor Overactivity

Belgium
Shanghai Institute of Acupuncture, Moxibustion...

Completed

The Long-term Efficacy of Electrical Pudendal Nerve Stimulation for the Urgency-Frequency Syndrome in Women

Urgency-frequency Syndrome

China
Astellas Pharma Inc

Completed

A Study to Assess Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder (ARIES)

Urinary Bladder, Overactive

United States, Canada
Astellas Pharma Inc

Completed

Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder (SCORPIO)

Urinary Bladder, Overactive

Australia, Belgium, France, Spain, Sweden, Bulgaria, Romania, Italy, Greece, South Africa, Austria, Poland, United Kingdom, Hungary, Denmark, Netherlands, Switzerland, Ireland, Lithuania, Russian Federation, Germany, Latvia, Slovakia, Finlan... and more
Astellas Pharma Inc

Completed

Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder (TAURUS)

Urinary Bladder, Overactive

Canada, Poland, Belgium, Spain, Sweden, United States, Romania, Italy, France, Austria, United Kingdom, Germany, Hungary, Australia, Denmark, Netherlands, Switzerland, Lithuania, Russian Federation, Latvia, South Africa, Slovakia, F... and more
Astellas Pharma Inc

Completed

A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder (CAPRICORN)

Urinary Bladder, Overactive

United States, Hungary, Canada, Spain, Finland, Slovakia, Czechia, Sweden, Germany, Denmark, Norway
Astellas Pharma Europe B.V.

Completed

Study to Test the Efficacy and Safety of YM178 in Subjects With Symptoms of Overactive Bladder (Blossom)

Urinary Bladder, Overactive

Belgium, Czech Republic, Germany, Spain, Sweden, United Kingdom
Saglik Bilimleri Universitesi Gulhane Tip Fakultesi

Completed

Behavioural Therapy Program for Female Overactive Bladder

Urinary Bladder, Overactive

Turkey
Pfizer

Completed

Study The Effects Of Different Doses Of UK-369,003 In Men With Overactive Bladder

Urinary Bladder, Overactive

Australia, France, Colombia, Germany, Canada, Finland, Slovakia, Spain, Switzerland, Italy, Chile, Greece, Latvia, Norway, Poland, United Kingdom
Astellas Pharma Inc

Completed

A Double-Blind, Paralleled Study Comparing Efficacy/Safety of Solifenacin to Tolterodine in Overactive Bladder Patients

Urinary Bladder, Overactive

China
The Methodist Hospital Research Institute

Recruiting

Neuromodulating Cortical Regions Involved in Neurogenic Bladder in MS (MSBLADDER)

Multiple Sclerosis | Overactive Bladder | Neurogenic Bladder

United States
Buddhist Tzu Chi General Hospital

Completed

Injections of Botulinum Toxin A in Treatment of Patients With Detrusor Overactivity and Impaired Contractility

Botulinum Toxins, Type A

Taiwan
University of Zurich
Swiss National Science Foundation; Balgrist University Hospital

Completed

Supraspinal Control of Lower Urinary Tract Function in Healthy Controls and Patients With Bladder Dysfunction

Multiple Sclerosis | Overactive Bladder | Spinal Cord Injury | Neurogenic Lower Urinary Tract Dysfunction

Switzerland
Boston Urogynecology Associates
Harvard University

Completed

Urodynamic Testing: Can we Improve Patient Experience?

Urinary Bladder, Overactive | Lower Urinary Tract Symptoms | Urinary Incontinence

United States
Astellas Pharma Europe B.V.

Completed

A Study to Evaluate the Efficacy, Safety and Tolerability of Mirabegron and Solifenacin Succinate Alone and in Combination for the Treatment of Overactive Bladder (Symphony)

Urologic Diseases | Urinary Bladder, Overactive | Urinary Bladder Diseases | Urological Manifestations | Signs and Symptoms

Belarus, Belgium, Czechia, Denmark, Finland, France, Germany, Hungary, Italy, Netherlands, Norway, Poland, Portugal, Romania, Russian Federation, Slovakia, Spain, Sweden, Ukraine, United Kingdom
Shanghai Institute of Acupuncture, Moxibustion...
RenJi Hospital

Completed

Comparison of Electrical Pudendal Nerve Stimulation and Tolterodine Tartrate for Urgency-Frequency Syndrome in Women

Urgency-frequency Syndrome

China
Astellas Pharma Europe B.V.

Completed

A Study to Evaluate Quality of Life in Patients Switched to Solifenacin From Other Antimuscarinics (VEST)

Urinary Bladder, Overactive

Czech Republic
Advanced Research Network
Astellas Pharma US, Inc.

Terminated

VESIcare For Improving OAB Symptoms in Patients Undergoing IGRT of the Prostate

Over-Active Bladder

United States
Astellas Pharma Inc

Completed

Study of VESIcare® In Overactive Bladder (OAB) Subjects to Evaluate Symptom Bother and Health Related Quality of Life (VIBRANT)

Urinary Bladder, Overactive

United States
Chang Gung Memorial Hospital

Completed

Comparative Study Between Behavior Therapy and Behavior Therapy Plus Mirabegron in Sexually Active Men With OAB Symptoms

Urinary Bladder, Overactive | Sexual Behavior | Sexual Function Disturbances | Behavior Therapy | Sexual Activity

Taiwan
Barrie Urology Associates
Astellas Pharma Canada, Inc.

Completed

Therapeutic Merit of Solifenacin in the Mitigation of Ureteral Stent-induced Pain and Lower Urinary Tract Symptoms

Urinary Bladder, Overactive | Flank Pain

Canada
Zhujiang Hospital

Recruiting

Safety and Efficacy of Botulinum Toxin A for Treatment of Overactive Bladder in Parkinson's Disease

Overactive Bladder | Parkinson's Disease | Onabotulinumtoxin A

China
HealthPartners Institute

Completed

Mirabegron in Parkinson Disease and Impaired Cognition (MICT-PD)

Overactive Bladder | Parkinson Disease | Impaired Cognition

United States
Northwestern University
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Completed

Microbiomes of Pelvic Pain

Overactive Bladder | Lower Urinary Tract Symptoms | Major Depression | Interstitial Cystitis | Chronic Prostatitis | Chronic Pelvic Pain Syndrome

United States

Clinical Trials on Urinblære, overaktiv

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kenya

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations